Skip to content
BALCAO · RETAIL-RETAIL STORES, NEC · SMALL CAP

Regenerative Medical Technology Group Inc. RMTG

9 fiscal years on record · USD · FY2025 reported · SEC filings only
$5.1M
▲ 24.2% YoY
$-7.8M
$-1.3M
▼ 306.1% YoY

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

We combine physician education and global influence through the International Society for Stem Cell Applications (ISSCA), advanced manufacturing and product innovation via Cellgenic, a premium clinical network delivering high-end patient care and generating real-world data, and a disciplined global expansion strategy. Our mission is to empower physicians globally to deliver the transformative benefits of regenerative medicine—stem cell therapies, exosomes, peptides, and advanced combination protocols—to patients seeking effective, natural alternatives to traditional surgical, palliative, or symptom-management approaches. Our revenue model is diversified and highly synergistic, encompassing professional training and certifications, recurring sales of Cellgenic products (exosomes, mesenchymal stem cells, peptides, and combination therapies), premium clinical treatments, equipment and kits, digital subscriptions, licensing, partnerships, and franchise arrangements.

Written from the business description in Regenerative Medical Technology Group Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 14 May 2026. Every sentence was checked against that document before publication.

Growth

USD 5.1M
Revenue, FY2025 · full 9-year series below
Revenue $M Net income $M
FY2025 · Revenue 5.1 · Net income -7.8
2M4M-5M-10M
2017202020232025
Compound annual growth
+49.4%
+147.4%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +147.4% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−153 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -17.0% · Net -153.2%
-500%-1000%
201720212025
ROE

Not applicable: equity was zero or negative in this period, so return on equity has no meaning.

Three returns, three denominators.
Return on equityNot applicable: equity was zero or negative in this period, so return on equity has no meaning.
Return on capital employedNot applicable: capital employed was zero or negative in this period, so return on capital employed has no meaning.
Gross margin55.1%
Operating margin-17.0%
Net margin-153.2%
EBITDAUSD -683,635.00

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -1.3
0.25M0.50M-0.50M-1.00M
201720212025

Total assetsUSD 4.5M
EquityUSD -34.7M
CashUSD 956,718.00
Gross debtUSD 21.1M
Net debtUSD 20.1M
Current ratio0.03×

Equity was zero or negative — liabilities equaled or exceeded assets. No ratio is shown.

The 9-year record

9 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
RMTG, 9-year financial record
Metric 202520242023202220212020201920182017
Revenue $B0.00.00.00.00.00.00.00.00.0
Operating income $B−0.00.0−0.0◌◌◌◌◌◌
EBITDA $B−0.00.0−0.0◌◌◌◌◌◌
Income tax $B−0.0−0.0−0.0−0.0−0.0◌◌◌◌
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.00.0−0.0−0.0◌−0.0−0.0−0.0◌
EPS, diluted $−0.62−0.44−0.79−0.45−1.12−0.63−0.47−0.50−0.11
Dividend / sh $◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend—————————
ROE % — not applicable: negative equity—————————
Shares out B0.010.010.010.010.010.010.010.000.00

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 45 reconciliationsAUDITED

Reconciled in 9 of the 9 fiscal years we could check. 20 checks were skipped: the balance sheet is not tagged before 2017. 10 checks were skipped: EPS is not tagged before 2017. 10 checks were skipped: revenue is not tagged before 2017.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityRetail-Retail Stores, NEC
Listed onOTC market
Incorporated innot stated in the filings
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2017

Share this section

Download image